The purpose of the program is to settle share-based incentive programs for employees and management where employees can acquire shares at 15% discount from market price.

The buyback will be carried out in accordance with Article 5 of the EU Market Abuse Regulation (MAR) and Commission Delegated Regulation (EU) 2016/1052, which provides a "safe harbour" from market manipulation rules for legitimate share repurchase program.

The parameters for the program are as follows:

• Maximum number of shares to be acquired: 31,365 shares
• Maximum total consideration: NOK 3.1 million
• Purchase price per share shall be between NOK 1.00 and NOK 100.00
• The program will be carried out during the period from 25 November 2025 to 5 December 2025
• The repurchases will be made on the Oslo Stock Exchange and will be executed by DNB Carnegie, a part of DNB Bank ASA, independently of the Company.

The Company will publish information about transactions carried out under the program in accordance with applicable regulations.

The authorization granted by the General Meeting allows the Board of Directors to acquire up to 5% of the Company's share capital, with a nominal value per share of NOK 1.00 per share.

This information is made public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

About ArcticZymes Technologies ASA

Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly listed, leading provider of novel and high-quality enzymes for use in molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company develops and manufactures salt-active nucleases and other specialty enzymes inspired by the Arctic environment, enabling robust performance under demanding process conditions. ArcticZymes is certified to ISO 13485 and manufactures under relevant ICH GMP standards. 
For more information, visit www.arcticzymes.com.